Modulating gut immunity and neoplasia with oral cytokine adjuvants

Özbilge, Hatice; LeVea, Charles; Chung, Andy; Li, Qingsheng; Egilmez, Nejat K.

doi:10.1080/2162402x.2014.1002724

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 In the subsequent studies, we obtained preliminary evidence that treatment could also block adenoma to adenocarcinoma transition in the APC min/C /Bacteroides fragilis (B. fragilis) model of colon cancer. 17 However, whether IL-10 would be effective in the long-term and how it suppresses the genesis and the progression of bona fide colon cancer were not investigated. In this manuscript, we report that oral IL-10 can promote effective long-term suppression of carcinoma in the APC min/C/ B. fragilis model and that the therapeutic effect is associated with the pleiotropic activity of IL-10 on multiple CD4 C T-cell subsets and cytotoxic CD8 C T-cells in the colonic LP.…”

Section: Introductionmentioning

confidence: 99%

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity

Jesus

Gallagher

et al. 2017

OncoImmunology

View full text Add to dashboard Cite

An oral sustained-release formulation of Interleukin-10 suppressed tumor growth and enhanced survival in the APC/ spontaneous colon cancer model. Therapeutic benefit was associated with a 5-fold reduction in CD4RORγtFoxp3IL-17 T-helper cell, CD4RORγtFoxp3IL-17 pathogenic T-regulatory cell and CD4RORγtFoxp3IL-17 conventional T-regulatory cell numbers and a concurrent 2-fold enhancement in CD8 T-cell activity in the colon. Selective subset depletion and functional blockade studies demonstrated that at steady-state CD4RORγtIL-17 T-cell subsets and CD4Foxp3 cTreg supported tumorigenesis, whereas CD8 cytotoxic T-lymphocytes impeded tumor progression following IL-10 therapy. Suppression of tumor growth by CD8 T-cells was associated with enhanced tumor infiltration and cytotoxic granule exocytosis. These findings establish the utility of oral IL-10 as a potential new therapeutic in the management of colon cancer and shed light on the cellular mechanisms that underlie its antitumor activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity

Jesus

Gallagher

et al. 2017

OncoImmunology

View full text Add to dashboard Cite

show abstract

Modulating gut immunity and neoplasia with oral cytokine adjuvants

Cited by 1 publication

References 10 publications

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity

Contact Info

Product

Resources

About

Modulating gut immunity and neoplasia with oral cytokine adjuvants

Cited by 1 publication

References 10 publications

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4+ T-cells and induction of antitumor CD8+ T-cell activity

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4+ T-cells and induction of antitumor CD8+ T-cell activity

Contact Info

Product

Resources

About

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity